Recarbrio (imipenem-cilastatin and relebactam) was approved for the treatment of hospital-acquired bacterial pneumonia (HABP) and ventilator-associated bacterial pneumonia (VABP).
List view / Grid view
Filter the results
The company announced the voluntary recall is due to low, out of specification dissolution test results in specific batches of its tetracycline products.
Researchers have found heart complications in patients diagnosed with bacterial pneumonia are more serious than in patients diagnosed with viral pneumonia...